Patent Report Sample Clauses

Patent Report. Each Party shall provide to the other Party, on a [ * ] basis, a patent report that includes the serial number, docket number and status of each Patent for which, pursuant to this Section 10.3, such Party has the right to direct the filing, prosecution and maintenance and which covers a Sole Invention or Joint Invention.
AutoNDA by SimpleDocs
Patent Report. FIBER OPTIC MAGNETIC FIELD SENSOR UNITED KINGDOM Owner: SPECTRAN CORPORATION Inventors - JAEGXX, XXXXXXX X.; XXLAXX, XXXX Xxx. No.: 2186072 JANUARY 31, 1986 Expires: JANUARY 31, 2006 PATENTED App. No.: 8602464.3 JANUARY 31, 1986 Ref: 003585-0002-002 ----------------------------------------------------------------------------- FIBER OPTIC MAGNETIC FIELD SENSOR FRANCE Owner: SPECTRAN CORPORATION Inventors - JAEGXX, XXXXXXX X.; XXLAXX, XXXX Xxx. No.: 8601457 FEBRUARY 03, 1986 Expires: FEBRUARY 03, 2006 PATENTED App. No.: 8601457 FEBRUARY 03, 1986 Ref: 003585-0002-004 ----------------------------------------------------------------------------- FIBER OPTIC MAGNETIC FIELD SENSOR SWEDEN Owner: SPECTRAN CORPORATION Inventors - JAEGXX, XXXXXXX X.; XXLAXX, XXXX Xxx. No.: 8600433-0 JANUARY 31, 1986 Expires: JANUARY 31, 2006 PATENTED App. No.: 8600433-0 JANUARY 31, 1986 Ref: 03580-0000-000 JAEGXX, Xxxxxxx X., XXLAXX, Xxxx ---------------------------------------------------------------------------- FIBER OPTIC MAGNETIC FIELD SENSOR UNITED STATES Inventors - JAEGXX, XXXXXXX X.; XXLAXX, XXXX Xxx. No.: 4,650,281 MARCH 17, 1987 PATENTED App. No.: 08/624,355 JUNE 25, 1984 Ref: 003585-0002-999 ---------------------------------------------------------------------------
Patent Report. MediCor Title Country Application No./Filing Date Patent. No./Reg. Date Owner Status Implant filling material and method US Federal 10/839559 May 5, 2004 Intellectual Property International, Inc. Pending Silicone mask for cryosurgery and method US Federal 95445089 May 19, 1995 5901707 May 11, 1999 HPL Biomedical, Inc. Expired Implantable prosthetic body used as implantable prostetic body, e.g. breast implants, comprises thin elastomeric container, and pliable viscous cohesive mass contained within container US Federal 533168 December 30, 2003 Intellectual Property International, Inc. Pending Mask to protect healthy tissue during cryosurgical removal of diseased tissue from the skin- is elastomer sheet with silicone gel layer on underside which remains adherent to skin at low temp. Australia AU 0000000 May 16, 1996 XX0000000 November 29, 1996 HPL Biomedical, Inc. Registered Mask to protect healthy tissue during cryosurgical removal of diseased tissue from the skin- is elastomer sheet with silicone gel layer on underside which remains adherent to skin at low temp. Brazil BR9612881 May 16, 1996 1996 BR 9612881 December 31, 2002 HPL Biomedical, Inc. Registered Breast implant European Patent WO 97951290 December 10, 1997 9826735 June 25, 1998 Laboratoires Eurosilicone Registered Anatomical breast implant with controllable and stable positioning European Patent EP2002790537 October 23, 2002 WO 2004041128 Laboratoires Eurosilicone Registered

Related to Patent Report

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Patent Filings The Party responsible for Prosecution and Maintenance of any Patent Rights as set forth in Section 7.2.2 and Section 7.2.3 will endeavor to obtain patent protection for a Product as it Prosecutes and Maintains its other patents Covering products in development, using counsel of its own choice but reasonably acceptable to the other Party, in such countries as the responsible Party sees fit.

  • Adverse Event Reporting Both Parties acknowledge the obligation to comply with the Protocol and / or applicable regulations governing the collection and reporting of adverse events of which they may become aware during the course of the Clinical Trial. Both Parties agree to fulfil and ensure that their Agents fulfil regulatory requirements with respect to the reporting of adverse events.

  • Licensed Patents Licensee shall be responsible for all further patent prosecution with respect to the Licensed Patents and Licensed Technologies set out in Exhibit “A”. Licensee may select the patent agent for the prosecution of the Licensed Patents, subject to the approval of Licensor as the patent owner, which approval will not be unreasonably withheld. Licensee shall provide Licensor with copies of all relevant documentation related to the filing and prosecution of the Licensed Patents so that Licensor may be informed and apprised of and meaningfully consulted as to the continuing prosecution. Licensor shall keep all such documentation confidential. In the event the Licensee does not agree that any given patent application or patent should be filed, prosecuted or maintained (hereinafter referred to as a “Refused Licensed Patent”) in a particular jurisdiction(s) Licensee shall indicate such disagreement in writing (hereinafter “Refusal Notice”) and upon Licensor’s receipt of such Refusal Notice Licensor shall have the right unilaterally to make, prosecute and maintain such Refused Licensed * Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission Patent in such jurisdiction(s) in the name of its owners, at Licensor’s expense, and Licensee shall not have any rights or obligations to such Refused Licensed Patent in such jurisdiction(s); provided, however, that Licensee shall retain all of its ownership rights in any Refused Licensed Patent that is a Co-Owned Technology. In such case Licensor shall provide Licensee with copies of all relevant documentation related to the filing and prosecution of the Refused Licensed Patents so that Licensee may be informed and apprised of and be meaningfully consulted with as to the continuing prosecution. Licensor shall have no obligation to continue prosecution or maintenance of any Refused Licensed Patent and may abandon same without any prior notice or any obligation to Licensee. Both Licensee and Licensor shall make best efforts to respond promptly to any request from the other Party for input or assistance with respect to matters pertaining to the Licensed Patents. Licensee shall use reasonable efforts to amend any patent application to include claims reasonably requested by the other Party and required to protect the Licensed Technology. In addition to Licensee’s obligations pursuant to section 4.1 above, Licensee shall be solely responsible for all patent and legal costs relating to the Licensed Patents and Licensed Technology (excluding Refused Licensed Patents) from the Effective Date onward, including all costs relating to the transfer of the Licensed Patents to the new patent agents selected by Licensee and approved by Licensor. For any patent and legal costs relating to the Licensed Patents and Licensed Technology (excluding Refused Licensed Patents) paid by Licensor after the Effective Date (including, without limitation, those expenses related to patentability assessments and drafting, filing, prosecution, maintenance, and taxes (the “Patent Costs”)), Licensee shall promptly reimburse Licensor for such Patent Costs upon receipt of an invoice from Licensor for such expenses. For any work in progress with respect to the Licensed Patents for which the Patent Costs have not already been paid by Licensor to its patent firm prior to the transfer of the Licensed Patents to Licensee’s patent agent, Licensor will direct its patent firm to copy Licensee on all such invoices from said patent firm and Licensee will promptly pay said invoices directly to Licensor’s patent firm.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • REPORT SUBMISSION 1. Copies of reporting packages for audits conducted in accordance with 2 CFR Part 200, Subpart F-Audit Requirements, and required by PART I of this form shall be submitted, when required by 2 CFR 200.512, by or on behalf of the recipient directly to the Federal Audit Clearinghouse (FAC) as provided in 2 CFR 200.36 and 200.512

  • Patent Applications It is understood by the parties that, pursuant to the Baylor Technology Transfer Agreement, MAS has the initial responsibility for filing, prosecution and maintenance of Patents and Patent Applications covering the Baylor Technology. The parties agree that, as between MAS and CTI, MAS shall be responsible for deciding whether and how to file, prosecute and maintain the Patents and Patent Applications, provided that:

  • Diversity Report The Contractor shall report to each Customer, spend with certified and other minority business enterprises. These reports shall include the period covered, the name, minority code and Federal Employer Identification Number of each minority business utilized during the period, Commodities provided by the minority business enterprise, and the amount paid to each minority business on behalf of each purchasing agency ordering under the terms of this Contract.

  • Product Information Contractor shall provide the following information for all goods provided pursuant to this Agreement: manufacturer’s name, product code number, and pack size.

Time is Money Join Law Insider Premium to draft better contracts faster.